A Protein 2,500x Sweeter Than Sugar Just Launched: What It Means for Kidney Stone Diets

July 28, 2026 — MycoTechnology, a Colorado-based food technology company, officially launched Zukora this week — a sweet protein derived from honey truffles that is approximately 2,500 times sweeter than sucrose (table sugar) by weight. The company partnered with stevia producer Adorvia to create a blended sweetener system, acknowledging that even a protein this potent requires complementary sweetness profiles to mimic sugar's sensory experience. For kidney stone patients, this announcement is not just food industry news — it is directly relevant to one of the most common dietary dilemmas stone formers face: how to satisfy a sweet tooth without consuming sugar loads that increase urinary calcium excretion or artificial sweeteners with unknown long-term metabolic effects.

Sugar, Sweeteners, and Kidney Stones: What the Data Shows

The relationship between sweeteners and kidney stone risk operates through multiple pathways:

• Sucrose (table sugar) and high-fructose corn syrup. High sugar intake increases urinary calcium excretion independently of dietary calcium intake. A 2024 study in the American Journal of Clinical Nutrition found that consuming 100g of sucrose in a single sitting increased 24-hour urinary calcium by 22% compared to an isocaloric starch meal. The proposed mechanism: sugar-induced insulin release reduces renal tubular calcium reabsorption. For a stone former already at risk, this is an unnecessary calcium load in the urinary space.
• Sugar and oxalate. High sugar consumption is correlated with diets that are also high in oxalate — chocolate (117 mg oxalate per 100g for dark chocolate), sweetened nut-based desserts (almonds at 469 mg oxalate per 100g), and sugary beverages often consumed alongside high-oxalate foods. The behavioral coupling of sugar and oxalate amplifies both risk factors simultaneously.
• Artificial sweeteners (aspartame, sucralose, saccharin). These have no direct effect on urinary calcium or oxalate. However, some studies suggest artificial sweeteners alter gut microbiome composition in ways that could theoretically affect oxalate-degrading bacteria like Oxalobacter formigenes, though the evidence is preliminary and inconsistent. The primary stone risk from artificial sweeteners is indirect: they perpetuate a sweet taste preference that drives consumption of other sweetened foods that may contain oxalate.
• Stevia (steviol glycosides). Stevia has no known effect on kidney stone risk. It does not increase urinary calcium, does not contain oxalate, and does not appear to alter gut oxalate metabolism. From a purely stone-prevention perspective, stevia is the safest of the commercially available high-intensity sweeteners. The limitation of stevia is its characteristic licorice-like aftertaste, which limits consumer acceptance at high concentrations.

Where Zukora (Sweet Protein) Fits In

Sweet proteins like Zukora (derived from the honey truffle, Mattiella species) function through a fundamentally different mechanism than small-molecule sweeteners. They bind to the T1R2-T1R3 sweet taste receptor on the tongue — the same receptor activated by sugar — but with vastly higher binding affinity. Because they are proteins, they are digested in the stomach and small intestine into constituent amino acids; they do not enter the bloodstream intact and do not trigger an insulin response. From a kidney stone perspective, the theoretical advantages are significant:

• Zero caloric load. No insulin response means no sugar-induced hypercalciuria.
• Protein digestion. The sweet protein is metabolized like any dietary protein — into amino acids used for tissue repair and energy. At the microgram-level doses required (a sweetener measured in milligrams, not grams), the renal acid load from protein metabolism is negligible.
• No known oxalate content. The protein is produced through precision fermentation (genetically engineered microorganisms producing the target protein in bioreactors), not extracted from the honey truffle mushroom itself. Fermentation-derived ingredients have no oxalate carryover from the source organism.

However, the current Zukora product is blended with stevia because sweet proteins have a slower sweetness onset and longer linger than sugar — a sensory mismatch that the stevia component corrects. The stevia component is benign for kidney stone patients; the combined product is likely as safe as stevia alone from a stone-prevention standpoint.

Practical Sweetener Guide for Stone Formers

The Practical Takeaway

Kidney stone patients do not need to completely eliminate sweetness from their diets. The evidence supports a practical hierarchy: (1) prefer stevia, monk fruit, or (when available) sweet proteins for daily use in coffee, tea, and homemade desserts; (2) use sugar, honey, or maple syrup sparingly — as occasional ingredients rather than staples; (3) avoid high-fructose corn syrup entirely due to its dual effects on urinary calcium and uric acid; (4) when choosing pre-sweetened foods, check both the sweetener type and the oxalate content of the food itself. A stevia-sweetened almond milk is still almond milk — the sweetener is benign but the oxalate content of almonds (469 mg per 100g) is not.

Use the free food search tool at OxalateWatch to check both oxalate content and nutritional composition for any food. For sweeteners specifically, the best approach is: look up the food you are sweetening first — if the base food is low-oxalate (white rice, yogurt, plain oatmeal, fresh fruit), you have flexibility in sweetener choice. If the base food is high-oxalate (almond flour, chocolate, spinach smoothies), no sweetener can offset that risk.

Source: Harvard T.H. Chan SPH (2024) oxalate data; American Journal of Clinical Nutrition (2024) sugar-calcium excretion study; MycoTechnology Zukora product announcement (July 2026); Food and Chemical Toxicology sweet protein safety review (2025).